Javascript must be enabled to continue!
Empagliflozin preserves mitochondrial function and reduces tubular injury in obese type 2 diabetic ZSF-1 rats
View through CrossRef
Abstract
Diabetic nephropathy remains the leading cause of end-stage renal disease. The ZSF-1 rat model combines features known as the metabolic syndrome, such as type 2 diabetes mellitus, hypertension and obesity, developing progressive kidney disease. In this study, we investigated the nephroprotective mechanisms of the SGLT2 inhibitor empagliflozin, focusing on mitochondrial function. Obese ZSF-1 rats were randomized at 24 weeks of age to receive either placebo or empagliflozin for eight weeks, while lean ZSF-1 rats served as healthy controls.
Kidney function, assessed by glomerular filtration rate (GFR), was significantly reduced in obese rats and was not improved by empagliflozin treatment. However, obese animals exhibited increased tubular injury, tubular cast formation, and elevated total and tubular proteinuria, all of which were attenuated by empagliflozin. Mitochondrial function was evaluated in freshly isolated cortical kidney mitochondria by measuring oxygen consumption. Obese ZSF-1 rats showed impaired respiratory capacity and reduced protein expression of oxidative phosphorylation (OXPHOS) complexes II, III, IV, and V, indicating mitochondrial dysfunction. Empagliflozin treatment improved mitochondrial function by enhancing complex I- and IV-linked respiration and restoring the expression of OXPHOS complexes II, III, and IV. In addition, empagliflozin treatment was linked to improved mitochondrial dynamics and modulation of autophagic activity, suggesting enhanced mitochondrial quality control.
Overall, these findings demonstrate that empagliflozin exerts nephroprotective effects primarily at the tubular level in obese ZSF-1 rats. The beneficial effects appear to be mediated through improved mitochondrial function, enhanced mitochondrial integrity, and reduced tubular injury.
Title: Empagliflozin preserves mitochondrial function and reduces tubular injury in obese type 2 diabetic ZSF-1 rats
Description:
Abstract
Diabetic nephropathy remains the leading cause of end-stage renal disease.
The ZSF-1 rat model combines features known as the metabolic syndrome, such as type 2 diabetes mellitus, hypertension and obesity, developing progressive kidney disease.
In this study, we investigated the nephroprotective mechanisms of the SGLT2 inhibitor empagliflozin, focusing on mitochondrial function.
Obese ZSF-1 rats were randomized at 24 weeks of age to receive either placebo or empagliflozin for eight weeks, while lean ZSF-1 rats served as healthy controls.
Kidney function, assessed by glomerular filtration rate (GFR), was significantly reduced in obese rats and was not improved by empagliflozin treatment.
However, obese animals exhibited increased tubular injury, tubular cast formation, and elevated total and tubular proteinuria, all of which were attenuated by empagliflozin.
Mitochondrial function was evaluated in freshly isolated cortical kidney mitochondria by measuring oxygen consumption.
Obese ZSF-1 rats showed impaired respiratory capacity and reduced protein expression of oxidative phosphorylation (OXPHOS) complexes II, III, IV, and V, indicating mitochondrial dysfunction.
Empagliflozin treatment improved mitochondrial function by enhancing complex I- and IV-linked respiration and restoring the expression of OXPHOS complexes II, III, and IV.
In addition, empagliflozin treatment was linked to improved mitochondrial dynamics and modulation of autophagic activity, suggesting enhanced mitochondrial quality control.
Overall, these findings demonstrate that empagliflozin exerts nephroprotective effects primarily at the tubular level in obese ZSF-1 rats.
The beneficial effects appear to be mediated through improved mitochondrial function, enhanced mitochondrial integrity, and reduced tubular injury.
Related Results
Empagliflozin in the Real World: Strengthening Heart Failure Care in Pakistan
Empagliflozin in the Real World: Strengthening Heart Failure Care in Pakistan
Heart failure with reduced ejection fraction (HFrEF) remains a major clinical challenge worldwide and is a pressing public health issue in Pakistan. Patients here often present at ...
The Validation and Determination of Empagliflozin Concentration in the Presence of Grapefruit Juice Using HPLC for Pharmacokinetic Applications
The Validation and Determination of Empagliflozin Concentration in the Presence of Grapefruit Juice Using HPLC for Pharmacokinetic Applications
Type 2 diabetes mellitus is a multifactorial disorder whose primary manifestation usually initiates with elevated blood sugar levels. Several antidiabetic agents are used to manage...
Circulating pro-angiogenic cells are preserved despite myocardial angiogenic signal deficits in HFpEF model
Circulating pro-angiogenic cells are preserved despite myocardial angiogenic signal deficits in HFpEF model
Abstract
Heart failure with preserved ejection fraction (HFpEF) has no cure, and microvascular dysfunction is a major contributing factor to its pathophysiology. ...
SCF Equations for T/Y and K Square-to-Round Tubular Joint
SCF Equations for T/Y and K Square-to-Round Tubular Joint
Summary
A parametric stress analysis of T/Y and K square-to-round tubular joints subjected to axial loads and in-plane and out-of-plane bending moments has been p...
Empagliflozin targeting STAT3/Akt/Nrf2 axis promoting diabetic wound healing in rat model
Empagliflozin targeting STAT3/Akt/Nrf2 axis promoting diabetic wound healing in rat model
BackgroundDiabetes mellitus (DM) and its complications pose a major global health challenge, with impaired wound healing leading to severe outcomes. Chronic inflammation, excessive...
Mitochondrial fusion promoter restores mitochondrial dynamics balance and ameliorates diabetic cardiomyopathy in an optic atrophy 1‐dependent way
Mitochondrial fusion promoter restores mitochondrial dynamics balance and ameliorates diabetic cardiomyopathy in an optic atrophy 1‐dependent way
AbstractAimImbalanced mitochondrial dynamics including suppressed mitochondrial fusion has been observed in diabetic hearts. However, it is still unknown whether mitochondrial fusi...
Empagliflozin-Metformin in Hypertension Therapy Synergistically Upregulate 3-Hydroxy-3-Methylglutaryl-Coenzyme A Synthase 2 and Acetyl-coenzyme A acyltransferase 1B
Empagliflozin-Metformin in Hypertension Therapy Synergistically Upregulate 3-Hydroxy-3-Methylglutaryl-Coenzyme A Synthase 2 and Acetyl-coenzyme A acyltransferase 1B
Background: Combination therapy of Empagliflozin (a Sodium Glucose Transporter 2 Inhibitor) and Metformin (a biguanide) is known to lower Blood Pressure (BP) and is particularly su...
Assessment of metals induced histopathological and gene expression changes in different organs of non-diabetic and diabetic rats
Assessment of metals induced histopathological and gene expression changes in different organs of non-diabetic and diabetic rats
AbstractDiabetes is a complex metabolic disorder and different environmental toxicants including heavy metals have been involved in diabetes induction. Therefore, assessment of the...

